T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease
Cancer Science · 2023
DOI: 10.1111/cas.15954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Satomi Okada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Neoplasms, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Adoptive immunotherapy using genetically engineered patient‐derived lymphocytes to express tumor‐reactive receptors is a promising treatment for malignancy. However, utilization of autologous T cells in this therapy limits the quality of gene‐engineered T cells, thereby inhibiting the timely infusion of the cells into patients. In this study, we evaluated the anti‐tumor efficacy and the potential to induce graft‐versus‐host disease (GVHD) in T cell receptor (TCR) gene‐engineered allogeneic T cells that downregulate the endogenous TCR and HLA class I molecules with the aim of developing an “off‐the‐shelf” cell product with expanded application of genetically engineered T cells. We transduced human lymphocytes with a high‐affinity TCR specific to the cancer/testis antigen NY‐ESO‐1 using a novel retrovirus vector with siRNAs specific to the endogenous TCR (siTCR vector). These T cells showed reduced expression of endogenous TCR and minimized reactivity to allogeneic cells in vitro. In non‐obese diabetic/SCID/γc null mice, TCR gene‐transduced T cells induced tumor regression without development of GVHD. A lentivirus‐based CRISPR/Cas9 system targeting β‐2 microglobulin in TCR gene‐modified T cells silenced the HLA class I expression and prevented allogeneic CD8 + T cell stimulation without disrupting their anti‐tumor capacity. This report is the first demonstration that siTCR technology is effective in preventing GVHD. Adoptive cell therapy with allogeneic T cells engineered with siTCR vector may be useful in developing an “off‐the‐shelf” therapy for patients with malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
- Takara Bio Inc., Shiga, Japan.
- Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Mie, Japan.
ORCID-Profile: Satomi Okada, Daisuke Muraoka, Naohiro Seo, Hiroaki Ikeda
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Okada, S., Muraoka, D., Yasui, K., Tawara, I., Kawamura, A., Okamoto, S., Mineno, J., Seo, N., Shiku, H., Eguchi, S., & Ikeda, H. (2023). T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease. Cancer Science. https://doi.org/10.1111/cas.15954
Vancouver
Okada S, Muraoka D, Yasui K, Tawara I, Kawamura A, Okamoto S, et al. T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease. Cancer Science. 2023. doi:10.1111/cas.15954
BibTeX
@article{Okada2023,
author = {Okada, Satomi and Muraoka, Daisuke and Yasui, Kiyoshi and Tawara, Isao and Kawamura, Ayumi and Okamoto, Sachiko and Mineno, Junichi and Seo, Naohiro and Shiku, Hiroshi and Eguchi, Susumu and Ikeda, Hiroaki},
title = {T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15954}
}
EUVIMED